Cooper Companies Inc (NYSE:COO) – Investment analysts at Northcoast Research increased their FY2019 EPS estimates for shares of Cooper Companies in a research note issued on Tuesday, December 3rd, according to Zacks Investment Research. Northcoast Research analyst D. Keiser now expects that the medical device company will post earnings of $12.35 per share for the year, up from their prior forecast of $12.32. Northcoast Research currently has a “Buy” rating on the stock. Northcoast Research also issued estimates for Cooper Companies’ Q4 2019 earnings at $3.30 EPS.
Cooper Companies (NYSE:COO) last released its quarterly earnings results on Thursday, December 5th. The medical device company reported $3.30 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.27 by $0.03. The firm had revenue of $691.60 million for the quarter, compared to the consensus estimate of $683.83 million. Cooper Companies had a return on equity of 17.38% and a net margin of 17.59%. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period last year, the business posted $2.87 EPS.
Other equities analysts have also recently issued research reports about the stock. KeyCorp increased their price objective on shares of Cooper Companies from $348.00 to $351.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 27th. Robert W. Baird reaffirmed a “buy” rating and set a $345.00 target price on shares of Cooper Companies in a report on Friday, December 6th. Zacks Investment Research upgraded shares of Cooper Companies from a “sell” rating to a “hold” rating and set a $325.00 price target on the stock in a research report on Wednesday, November 20th. ValuEngine downgraded shares of Cooper Companies from a “buy” rating to a “hold” rating in a research report on Tuesday, September 10th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $344.00 price objective on shares of Cooper Companies in a research note on Friday, December 6th. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the stock. Cooper Companies currently has an average rating of “Buy” and an average price target of $328.73.
Cooper Companies stock traded up $1.10 during mid-day trading on Thursday, reaching $321.11. 183,000 shares of the stock traded hands, compared to its average volume of 319,339. Cooper Companies has a 12-month low of $241.72 and a 12-month high of $344.32. The stock has a market capitalization of $15.73 billion, a PE ratio of 26.00, a price-to-earnings-growth ratio of 2.33 and a beta of 0.92. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.05 and a quick ratio of 0.59. The business’s 50-day moving average is $309.49 and its 200-day moving average is $313.88.
A number of large investors have recently modified their holdings of COO. Nomura Holdings Inc. raised its holdings in Cooper Companies by 73.8% during the third quarter. Nomura Holdings Inc. now owns 44,543 shares of the medical device company’s stock valued at $13,051,000 after acquiring an additional 18,909 shares during the period. Resources Management Corp CT ADV bought a new position in shares of Cooper Companies in the third quarter worth about $240,000. Maverick Capital Ltd. purchased a new stake in shares of Cooper Companies during the third quarter worth about $1,082,000. Squarepoint Ops LLC grew its position in shares of Cooper Companies by 78.1% during the third quarter. Squarepoint Ops LLC now owns 32,542 shares of the medical device company’s stock worth $9,665,000 after purchasing an additional 14,272 shares in the last quarter. Finally, National Pension Service raised its stake in Cooper Companies by 5.5% during the 3rd quarter. National Pension Service now owns 74,797 shares of the medical device company’s stock valued at $22,215,000 after purchasing an additional 3,872 shares during the period. 95.35% of the stock is currently owned by institutional investors and hedge funds.
Cooper Companies Company Profile
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
